Organization
The Aurum Institute
5 clinical trials
Clinical trial
Safety, Tolerability and Drug-drug Interactions of Short-course Treatment of Latent Tuberculosis Infection With High-dose Once-weekly Rifapentine and Isoniazid (3HP) Among Infants, Children and Adolescents Living With HIV Taking Dolutegravir-based Antiretroviral TreatmentStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized Trial Comparing Treatment Completion of Daily Rifapentine & Isoniazid for One Month (1HP) To Weekly Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in HIV-negative Household Contacts of Recently Diagnosed Tuberculosis Patients, The "One To Three" TrialStatus: Recruiting, Estimated PCD: 2024-10-28
Clinical trial
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIVStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Novel 4-month Pan-TB Regimen Targeting Both Host and Microbe (panTB-HM)Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Safety, Tolerability, and Drug-drug Interactions of Short-course Treatment of Latent Tuberculosis Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventative Therapy Among HIV-infected Patients Taking Dolutegravir-based Antiretroviral TreatmentStatus: Completed, Estimated PCD: 2022-12-07